In today’s podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients.
Industry News
News from pharmaceutical companies and other related healthcare organizations
Our chat with Giacomo Chiesi
January 11, 2024
In today’s podcast, we talk with Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, where he leads a team in developing and marketing treatments for rare and ultra-rare diseases.
Somavert turns twenty: the pegvisomant story
December 27, 2023
From J D Faccinetti, Co-founder and Chief Editor – When you deal with a chronic pituitary disease, you get close to your medications, just like you would to a friend. This was my experience with
The symphony of collaboration: It’s the only way beautiful music happens!
August 1, 2023
From the desk of J. D. Faccinetti, co-founder – We are big fans; collaboration works. Our experience and research suggest that when collaboration between organizations is strong, learning improves, and outcomes…
The endocrine world gathers in Chicago
June 20, 2023
By J D Faccinetti, co-founder – In a three-day conference packed with thousands of scientists, endocrinologists, industry, and researchers, ENDO 2023 Conference presented a comprehensive review of the latest in pituitary disease advances, treatment, management, developments,
Acroline™ – Helping you live well with Acromegaly
November 9, 2022
Acroline™ is a series of four brochures created by Pfizer in collaboration with an international panel of people with acromegaly, acromegaly support groups, and health psychologists. This series of supportive guides and tools are designed to help keep your life on track and live well with acromegaly.
Another great support resource for people with acromegaly
October 27, 2022
We take advantage of Acromegaly Day, coming up on November 1, to highlight resources from industry partners. The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. PALs work with
Recordati Rare Diseases provides access to the LINC 4 study in the Journal of Clinical Endocrinology and Metabolism (JCEM).
June 22, 2022
This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
A conversation with Amryt’s new president for the Americas, Sheila Frame
June 7, 2022
We caught up with Sheila a few weeks ago at the Acromegaly Community Conference near San Francisco. We had a captivating chat about Mycapssa (oral octreotide) and about Amryt’s start in Dublin, Ireland, just six years ago, its philosophy, brand, and plans.
Good news from Amryt for acromegaly patients in Europe
March 22, 2022
Amryt Pharma announced positive results for the MPOWERED phase 3 trial for Mycapssa® oral octreotide for acromegaly patients, in a recent press release. The trial paves the way for the approval of Mycapssa® by the EMA.
Corcept’s Grace Study for a new Cushing’s drug; an update
February 22, 2022
The Corcept Therapeutics “Grace Study”, designed to evaluate the benefits and side effects of a new medication for people with endogenous Cushing’s syndrome, continues full steam ahead. The company recently announced the availability of new
Emotional wellness with acromegaly
September 7, 2021
Kudos to Pfizer’s new series on patient support. The first one features critical advice on emotional and mental help support! The materials provide valuable content given the importance of mental health issues to acromegaly patients.
Big news for acromegaly at Crinetics
July 12, 2021
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly